Arterial hypertension related to sunitinib
Journal Title: OncoReview - Year 2011, Vol 1, Issue 3
Abstract
Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide production and reduced microvascular density. Clinically, this results in increased peripheral vascular resistance and consequently increase in blood pressure. The diagnosis of iatrogenic arterial hypertension should be in accordance with the guidelines of the European Society of Hypertension and the Polish Society of Hypertension. Home blood pressure measurements are very useful but 24-hour ambulatory blood pressure monitoring is necessary in some cases. Early diagnosis of iatrogenic hypertension gives opportunity to apply the optimal antihypertensive treatment and to prevent cardiotoxicity. When choosing antihypertensive agents it is important to be awared of coexisting diseases, these drugs should not interact with sunitinib. Hypertension related to sunitinib is the positive predictive factor of anticancer therapy and that is why sunitinib discontinuation due to hypertension should be very rare.
Authors and Affiliations
Sebastian Szmit, Krzysztof Filipiak, Magdalena Zaborowska, Agnieszka Gębara-Puchniarz, Cezary Szczylik
Keywords
Related Articles
- EP ID EP53114
- DOI -
- Views 207
- Downloads 0
Nowe możliwości leczenia uogólnionego raka piersi
Mimo udoskonalania metod badań przesiewowych, wczesnego wykrywania raka piersi i nowych terapii rokowanie w raku piersi pozostaje złe. Zaawansowany, uogólniony rak piersi jest chorobą przewlekłą, nieuleczalną. Podstawową...
Ifosfamide-induced encephalopathy in a patient with metastatic fibrosarcoma
Ifosfamide is a cytostatic drug commonly used in chemotherapy. One of the common adverse effects resulting from the treatment with ifosfamide is encephalopathy. This paper describes a case study of a 64-year-old patient...
The evaluation of the efficacy and toxicity of targeted treatment in non-small cell lung cancer patients – single centre experience
Introduction: Tyrosine kinase inhibitors (TKI) are the standard of treatment in patients with advanced non-small cell lung cancer (NSCLC) with EGFR (endothelial growth factor receptor) gene activating mutation. Objecti...
Quality of life in oncology and quality of life in course of molecularly targeted therapy in patients diagnosed with metastatic renal-cell carcinoma
Introduction of molecularly targeted agents into clinical practice has led to marked progress in pharmacotherapy of advanced renal cell carcinoma. There have been six drugs of the therapeutic class registered to date. Fu...
Chemotherapy-related nephrotoxicity
The development of oncology and increasing prevalence of cancer is associated with rapidly growing group of patients treated with chemotherapeutic agents, which, with the benefits of their use, poses a risk of side effec...